Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570373 · ClinicalTrials.gov registry record · Phase 1
A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02570373 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 8 participants.
The verdict
NCT02570373, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the elimination of guselkumab glycoform variants following a single intravenous (IV) administration of guselkumab at a 10 milligram per kilogram (mg/kg) dose in healthy participants.
Interventions
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-09-25 |
| Est. Completion | 2016-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570373
The ClinicalTrials.gov registry entry for NCT02570373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guselkumab is the first listed.
NCT02570373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02570373 about?
NCT02570373 is a clinical study titled "A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants". The purpose of this study is to characterize the elimination of guselkumab glycoform variants following a single intravenous (IV) administration of guselkumab at a 10 milligram per kilogram (mg/kg) dose in healthy participants.
What is the current status of trial NCT02570373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-09-25. Estimated completion is 2016-01-12.
What interventions are being tested in trial NCT02570373?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT02570373?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.